Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

Stem Cell Reports
Rafael Diaz de la GuardiaPablo Menendez

Abstract

Bone marrow mesenchymal stem/stromal cells (BM-MSCs) are key components of the hematopoietic niche thought to have a direct role in leukemia pathogenesis. BM-MSCs from patients with acute myeloid leukemia (AML) have been poorly characterized due to disease heterogeneity. We report a functional, genetic, and immunological characterization of BM-MSC cultures from 46 AML patients, stratified by molecular/cytogenetics into low-risk (LR), intermediate-risk (IR), and high-risk (HR) subgroups. Stable MSC cultures were successfully established and characterized from 40 of 46 AML patients irrespective of the risk subgroup. AML-derived BM-MSCs never harbored tumor-specific cytogenetic/molecular alterations present in blasts, but displayed higher clonogenic potential than healthy donor (HD)-derived BM-MSCs. Although HD- and AML-derived BM-MSCs equally provided chemoprotection to AML cells in vitro, AML-derived BM-MSCs were more immunosuppressive/anti-inflammatory, enhanced suppression of lymphocyte proliferation, and diminished secretion of pro-inflammatory cytokines. Multivariate analysis revealed that the level of interleukin-10 produced by AML-derived BM-MSCs as an independent prognostic factor negatively affected overall survival. Col...Continue Reading

Citations

Dec 10, 2017·Cellular and Molecular Life Sciences : CMLS·Marie GoulardDominique Bonnet
Sep 30, 2017·Stem Cells·Siddaraju V BoregowdaDonald G Phinney
Jan 25, 2019·Current Stem Cell Research & Therapy·Marietta Herrmann, Franz Jakob
Apr 30, 2019·Current Opinion in Hematology·Il-Hoan OhJin-A Kim
Jan 22, 2020·British Journal of Haematology·Marilena Ciciarello, Antonio Curti
Sep 25, 2018·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Paulina Podszywalow-BartnickaKatarzyna Piwocka
May 5, 2020·The Journal of Clinical Investigation·Alexander WaclawiczekDominique Bonnet
May 24, 2020·Journal of Clinical Medicine·Alice PievaniMarta Serafini
Sep 28, 2017·Stem Cells International·Nicola Stefano FracchiollaAgostino Cortelezzi
Sep 28, 2018·Stem Cell Research & Therapy·Ben AntebiLeopoldo C Cancio
May 30, 2019·Cancer Cell International·Mugdha SharmaSweta Srivastava
Feb 20, 2020·Molecular Therapy. Methods & Clinical Development·Graça Almeida-PoradaChristopher D Porada
May 10, 2020·Haematologica·Alice PievaniMarta Serafini
Apr 4, 2021·Cytokine·Omid Karimdadi SarianiFarhad Zaker
Apr 8, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Salvatore Fiorenza, Cameron J Turtle
Jul 3, 2021·Journal of Clinical Medicine·Suncica Kapor, Juan F Santibanez
Jul 25, 2021·Leukemia·Sarah TettamantiMarta Serafini
Aug 20, 2021·Blood·Marta Derecka
Aug 20, 2021·Stem Cell Reviews and Reports·Lauren S ShermanPranela Rameshwar
Sep 2, 2021·Blood Advances·Rafael Díaz de la GuardiaPablo Menéndez

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
flow-cytometry
MDS

Software Mentioned

ISIS
IKAROS
SPSS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.